Abstract: Vacuum-integrated photoresist-less methods and apparatuses for forming metal hardmasks can provide sub-30 nm patterning resolution. A metal-containing (e.g., metal salt or organometallic compound) film that is sensitive to a patterning agent is deposited on a semiconductor substrate. The metal-containing film is then patterned directly (i.e., without the use of a photoresist) by exposure to the patterning agent in a vacuum ambient to form the metal mask. For example, the metal-containing film is photosensitive and the patterning is conducted using sub-30 nm wavelength optical lithography, such as EUV lithography.

Abstract: The present invention relates to a hair straightening apparatus having two arms pivotably coupled together and a heating plate on a facing side of at least one arm. A central pack disposed between the first arm and the second arm and coupled to the hair styling apparatus at the hinge end and a biasing means adapted to support the central pack symmetrically between the first arm and the second arm.

Abstract: A sole for an article of footwear includes an outsole that has longitudinal ribs and a midsole that is disposed above the outsole and that defines notches. The longitudinal ribs arc disposed in the notches.

Abstract: The present invention relates to specific binding members, particularly antibodies and fragments thereof, which bind to amplified epidermal growth factor receptor (EGFR) and to the de2-7 EGFR truncation of the EGFR. In particular, the epitope recognized by the specific binding members, particularly antibodies and fragments thereof, is enhanced or evident upon aberrant post-translational modification. These specific binding members are useful in the diagnosis and treatment of cancer. The binding members of the present invention may also be used in therapy in combination with chemotherapeutics or anti-cancer agents and/or with other antibodies or fragments thereof.

Abstract: The present invention relates to specific binding members, particularly antibodies and fragments thereof, which bind to amplified epidermal growth factor receptor (EGFR) and to the de2-7 EGFR truncation of the EGFR. In particular, the epitope recognized by the specific binding members, particularly antibodies and fragments thereof, is enhanced or evident upon aberrant post-translational modification. These specific binding members are useful in the diagnosis and treatment of cancer. The binding members of the present invention may also be used in therapy in combination with chemotherapeutics or anti-cancer agents and/or with other antibodies or fragments thereof.

Abstract: The invention relates to a drilling fluid in the form of a water-in-oil (W/O) emulsion comprising at least components (A) to (D), wherein component (D) is at least one (meth)acrylic copolymer, which contains at least one of structural units (D1), (D2) and (D3) to introduce at least one hydroxyl and/or amino functionality into the copolymer and which further contains at least one structural unit (D4), a use of said (meth)acrylic copolymer as rheological agent in drilling fluids, which are water-in-oil (W/O) emulsions, as well as to a method of producing oil and/or natural gas or of preparing the production thereof comprising the step of using the inventive drilling fluid for generating and/or operating a drill hole.

Abstract: The invention relates to a drilling fluid in the form of a water-in-oil (W/O) emulsion comprising at least components (A) to (D), wherein component (D) is at least one (meth)acrylic copolymer, which contains at least one of structural units (D1), (D2) and (D3) to introduce at least one hydroxyl and/or amino functionality into the copolymer and which further contains at least one structural unit (D4), a use of said (meth)acrylic copolymer as rheological agent in drilling fluids, which are water-in-oil (W/O) emulsions, as well as to a method of producing oil and/or natural gas or of preparing the production thereof comprising the step of using the inventive drilling fluid for generating and/or operating a drill hole.

Abstract: The present invention relates generally to the membrane transporter NaPi2b (SLC34A2) as a target for therapy, including immunotherapy, and particularly cancer therapy. The SLC34A2 epitope peptide encompassing amino acids 312-340 of SLC34A2 has been identified as an ovarian cancer epitope using the monoclonal antibody MX35. The invention also relates to the use of SLC34A2 and particularly SLC34A2 peptides in generating antibodies which have anti-tumor or anti-cancer activity or in stimulating an immunological response. The invention further relates to antibodies specifically directed against NaPi2b (SLC34A2) and the SLC34A2 peptide(s), including veneered, chimeric, single chain and humanized antibodies. Methods for generating an immune response and for treatment of tumors and cancer are also provided. Assays for screening and identifying compounds directed against SLC34A2, including the SLC34A2 epitope peptide, and additional antibodies are provided.

Abstract: Techniques for real-time offer evaluations are presented. An enterprise system detects and interaction with a customer. Metrics for the interaction are acquired and a centralized preference server delivers real time preference values known for the customer. The metrics and the preference values are used to dynamically and in real-time evaluate conditions for an enterprise offer and when met the offer is delivered to the customer in real time.

Abstract: The present invention relates to specific binding members, particularly antibodies and fragments thereof, which bind to amplified epidermal growth factor receptor (EGFR) and to the de2-7 EGFR truncation of the EGFR. In particular, the epitope recognized by the specific binding members, particularly antibodies and fragments thereof, is enhanced or evident upon aberrant post-translational modification. These specific binding members are useful in the diagnosis and treatment of cancer. The binding members of the present invention may also be used in therapy in combination with chemotherapeutics or anti-cancer agents and/or with other antibodies or fragments thereof.

Abstract: The present invention relates generally to the membrane transporter NaPi2b (SLC34A2) as a target for therapy, including immunotherapy, and particularly cancer therapy. The SLC34A2 epitope peptide encompassing amino acids 312-340 of SLC34A2 has been identified as an ovarian cancer epitope using the monoclonal antibody MX35. The invention also relates to the use of SLC34A2 and particularly SLC34A2 peptides in generating antibodies which have anti-tumor or anti-cancer activity or in stimulating an immunological response. The invention further relates to antibodies specifically directed against NaPi2b (SLC34A2) and the SLC34A2 peptide(s), including veneered, chimeric, single chain and humanized antibodies. Methods for generating an immune response and for treatment of tumors and cancer are also provided. Assays for screening and identifying compounds directed against SLC34A2, including the SLC34A2 epitope peptide, and additional antibodies are provided.

Abstract: The present invention relates generally to the membrane transporter NaPi2b (SLC34A2) as a target for therapy, including immunotherapy, and particularly cancer therapy. The SLC34A2 epitope peptide encompassing amino acids 312-340 of SLC34A2 has been identified as an ovarian cancer epitope using the monoclonal antibody MX35. The invention also relates to the use of SLC34A2 and particularly SLC34A2 peptides in generating antibodies which have anti-tumor or anti-cancer activity or in stimulating an immunological response. The invention further relates to antibodies specifically directed against NaPi2b (SLC34A2) and the SLC34A2 peptide(s), including veneered, chimeric, single chain and humanized antibodies. Methods for generating an immune response and for treatment of tumors and cancer are also provided. Assays for screening and identifying compounds directed against SLC34A2, including the SLC34A2 epitope peptide, and additional antibodies are provided.

Abstract: Techniques for universal promotion conditions for offer evaluations are provided. Promotions are comprised of promotion conditions. The conditions are defined as a key value, description, and data type. Defined operators for the data types are enumerated and the key values can be mixed and matched in custom defined conditional statements to expand promotional engines with universal promotion conditions.

Abstract: The test meter includes a strip port connector configured and sized to receive a test strip and including a plurality of spaced electrical contacts disposed in an array upon a printed circuit board (PCB). Upon insertion of a test strip in the strip port connector, at least some of the plurality of spaced electrical contacts of the strip port connector are caused to engage each of the electrical contacts of the inserted test strip and in which a plurality of disparate test strip designs can be used in connection with the test meter and in which the array of electrical contacts of the strip port connector are disposed in parallel relation to the substantially planar surface of the inserted test strip and are brought into contact therewith for identifying the test strip and subsequent testing.

Abstract: The present invention relates to specific binding members, particularly antibodies and fragments thereof, which bind to amplified epidermal growth factor receptor (EGFR) and to the de2-7 EGFR truncation of the EGFR. In particular, the epitope recognized by the specific binding members, particularly antibodies and fragments thereof, is enhanced or evident upon aberrant post-translational modification. These specific binding members are useful in the diagnosis and treatment of cancer. The binding members of the present invention may also be used in therapy in combination with chemotherapeutics or anti-cancer agents and/or with other antibodies or fragments thereof.

Abstract: The present invention relates generally to the membrane transporter NaPi2b (SLC34A2) as a target for therapy, including immunotherapy, and particularly cancer therapy. The SLC34A2 epitope peptide encompassing amino acids 312-340 of SLC34A2 has been identified as an ovarian cancer epitope using the monoclonal antibody MX35. The invention also relates to the use of SLC34A2 and particularly SLC34A2 peptides in generating antibodies which have anti-tumor or anti-cancer activity or in stimulating an immunological response. The invention further relates to antibodies specifically directed against NaPi2b (SLC34A2) and the SLC34A2 peptide(s), including veneered, chimeric, single chain and humanized antibodies. Methods for generating an immune response and for treatment of tumors and cancer are also provided. Assays for screening and identifying compounds directed against SLC34A2, including the SLC34A2 epitope peptide, and additional antibodies are provided.

Abstract: The present invention relates to specific binding members, particularly antibodies and fragments thereof, which bind to amplified epidermal growth factor receptor (EGFR) and to the de2-7 EGFR truncation of the EGFR. In particular, the epitope recognized by the specific binding members, particularly antibodies and fragments thereof, is enhanced or evident upon aberrant post-translational modification. These specific binding members are useful in the diagnosis and treatment of cancer. The binding members of the present invention may also be used in therapy in combination with chemotherapeutics or anti-cancer agents and/or with other antibodies or fragments thereof.

Abstract: The present disclosure relates generally to the membrane transporter NaPi2b (SLC34A2) as a target for therapy, including immunotherapy, and particularly cancer therapy. The SLC34A2 epitope peptide encompassing amino acids 312-340 of SLC34A2 has been identified as an ovarian cancer epitope using the monoclonal antibody MX35. The invention also relates to the use of SLC34A2 and particularly SLC34A2 peptides in generating antibodies which have anti-tumor or anti-cancer activity or in stimulating an immunological response. The invention further relates to antibodies specifically directed against NaPi2b (SLC34A2) and the SLC34A2 peptide(s), including veneered, chimeric, single chain and humanized antibodies. Methods for generating an immune response and for treatment of tumors and cancer are also provided. Assays for screening and identifying compounds directed against SLC34A2, including the SLC34A2 epitope peptide, and additional antibodies are provided.

Abstract: Systems and techniques for centralized user preference management for electronic decision making devices are provided. A user preference profile is received. A user preference profile manager may transmit a user preference from the user preference profile to a requesting user transaction terminal. the user preference manager may also receive a dynamic user preference from a user preference profile and extend the user preference profile with the dynamic user preference, where the dynamic user preference includes a preference definition and the preference definition includes read and write access controls for the dynamic user preference. Then the user manager may update the user preference profile based on data received from the user transaction terminal.

Abstract: An insertion device configured to provide access to a treatment site within a body cavity (e.g., an abdominal cavity) is provided herein. In general, the device includes any type of elongate sleeve (e.g., a trocar) having an inner lumen. Further, the device includes a tissue retraction mechanism configured to extend from a distal end of the sleeve wherein the tissue retraction mechanism is configured to securely engage a cavity wall such that in response to a retraction force the mechanism can pull the cavity wall over the distal end of the sleeve thereby positioning the sleeve across the cavity wall. Additionally, various embodiments of a method for providing access to a body cavity are also provided herein.